Navigation Links
Celsion Corporation Announces Convertible Preferred Stock Financing and Amended License Agreement for Aggregate Gross Proceeds of up to $9 Million
Date:1/13/2011

Committee permitting the resumption of enrollment of Japanese patients in the Japan cohort of the study.  In consideration of these accelerated milestone payments from Yakult, the Company has agreed to reduce future drug approval milestone payments by approximately 40%. Among other separate prescribed events, receipt by the Company of the second $2.0 million from Yakult is a mandatory conversion event for the convertible preferred stock.

The transaction is expected to close on or about January 14, 2011, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the sale of the Units pursuant to this offering for general corporate purposes, including the funding of the clinical development of its product pipeline of cancer drugs.

Michael H. Tardugno, Celsion's President and Chief Executive Officer, commented, "Through an innovative, shareholder-minded approach to financing, Celsion has secured the capital that is expected to enable it to meet certain key clinical goals at terms that are supportive of all our shareholders.  We believe that we now have the financial runway sufficient to complete enrollment in our Phase III primary liver cancer trial, the HEAT study, as well as other related clinical and CMC milestones in 2011.

All of the shares of preferred stock and warrants to purchase shares of common stock are being offered pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission (the "SEC"), which was declared effective by the SEC on April 17, 2009, as supplemented by a prospectus supplement dated January 12, 2011 filed with the Securities and Exchange Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended.

Dominick & Dominick LLC acted as placement agent for the offering.  The Units may only be offered by means of a prospectus. Copies of the prospectus supplement and accompanying base prospectus
'/>"/>

SOURCE Celsion Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Celsion Announces Date and Time Change for Third Quarter 2010 Financial Results Conference Call to Monday, November 15, 2010
2. Celsion Reports Third Quarter 2010 Financial Results and Provides Business Update
3. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
4. Pharmos Corporation Reports 2008 Second Quarter Results
5. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
6. Genaera Corporation Announces Second Quarter Financial Results
7. MannKind Corporation Reports Second Quarter Financial Results
8. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
9. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
10. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... USA (PRWEB) November 26, 2014 Biomedical ... accuracy, additive systems to enable 3D manufacture at the ... road conditions are among finalists in nine categories for ... The awards are sponsored by SPIE, the international ... Media . , Winners will be announced by industry ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 2014 ... is a professional and in-depth research report on ... information, like its definition, classification, application, and industry ... report covers the international market analysis, including China’s ... the US, Europe, Asia, China, Japan etc. regions) ...
(Date:11/26/2014)... YORK , Nov. 26, 2014 The ... may indicate the company is looking to expand in ... further sales.  The healthcare market research firm says that  ... to Kalorama Information,s biennial survey of the IVD market ... and any change in its composition would likely affect ...
(Date:11/26/2014)... November 26, 2014 On January, 14, ... Baltimore and Washington D.C. science community to the UMBC ... event, sponsored by the Protein Society, will take place ... Center, Room 312. Through discussion, presentations and workshops, ... importance of proteins, their role in the industry and ...
Breaking Biology Technology:Finalists Named for 2015 Prism Awards for Photonics Innovation 2Finalists Named for 2015 Prism Awards for Photonics Innovation 3Finalists Named for 2015 Prism Awards for Photonics Innovation 4Finalists Named for 2015 Prism Awards for Photonics Innovation 5Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 2Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 3Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2
... Renowned Clinicians in the Fields of Cancer and Women,s Health ... to Best ... Address Current Medical Needs, REHOVOT, Israel and ... ROSG) announced,today the establishment of its Medical Advisory Board. Rosetta ...
... Pa., Feb. 4 Centocor, Inc. announced today,that ... 1275),has been accepted for review by the U.S. ... adult patients with chronic moderate to severe plaque,psoriasis. ... a novel,mechanism of action that targets the cytokines ...
... Aricept Prescription Rates, According to a New Report from Decision ... ... Feb. 4 Decision Resources, one of the,world,s leading research and ... owns a dominating,42.4% patient share for first-line treatment of newly diagnosed ...
Cached Biology Technology:Rosetta Genomics Establishes Medical Advisory Board 2Rosetta Genomics Establishes Medical Advisory Board 3Rosetta Genomics Establishes Medical Advisory Board 4Rosetta Genomics Establishes Medical Advisory Board 5Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA 2Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA 3Eisai/Pfizer's Aricept Owns a Dominating 42.4% Patient Share for First-Line Treatment of Alzheimer's Disease 2Eisai/Pfizer's Aricept Owns a Dominating 42.4% Patient Share for First-Line Treatment of Alzheimer's Disease 3
(Date:11/21/2014)... REDMOND, Wash. , Nov. 20, 2014 ... access for the Internet of Things (IoT), today announced ... position of chief operating officer. Previously a strategic advisor ... marketing, finance, and operations. Mr. Traynor is based out ... . He reports to Chris Muench , ...
(Date:11/18/2014)... Nov. 18, 2014   EyeLock Inc. , ... and MorphoTrust USA (Safran), a leading ... announced a strategic partnership to offer comprehensive biometric ... administration (MVA), airport screening and financial services markets. ... MorphoTrust serves consumers through a nationwide network of ...
(Date:11/7/2014)... Researchers led by Dr. Debra Auguste, associate professor, ... at The City College of New York, have ... treatment for one of the most aggressive forms ... (TNBCs) have a high mortality rate owing to ... effective therapeutic options. However, Professor Auguste,s team, discovered ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... The March of Dimes has extended its Prematurity Campaign ... address preterm birth globally. The expansion, announced at the ... the national action plan being created during the two-day ... birth. "The March of Dimes Prematurity Campaign has ...
... shot of youthful vigor in a stem cell experiment by ... for research on new treatments for age-related degenerative conditions such ... a new study to be published June 15 in an ... identified two key regulatory pathways that control how well adult ...
... has received $400,000 from the National Oceanic and Atmospheric ... system for the Mid-Atlantic region, spanning the waters from ... to the continental shelf. Nearly 25 percent of the ... initiative is part of the national Integrated Ocean Observing ...
Cached Biology News:March of Dimes announces Prematurity Campaign expansion at Surgeon General's conference 2March of Dimes announces Prematurity Campaign expansion at Surgeon General's conference 3Stem cell researchers give old muscle new pep 2Stem cell researchers give old muscle new pep 3Stem cell researchers give old muscle new pep 4UD nets NOAA funding for Mid-Atlantic ocean observing 2
... LAS-3000 imaging system combines new CCD ... interface, providing significantly improved system sensitivity ... The system is especially dedicated to ... system for Western blotting applications.,Fuiji's LAS-3000 ...
This kit is designed to select cells labeled with biotinylated antibodies. Kit includes reagents for labeling 3 x 10 9 cells and EasySep magnet....
... The Fujifilm Life Science LAS-3000mini ... especially dedicated to chemiluminescence applications, and ... blotting applications., Fuiji 's LAS-3000 provides ... and digitization. , Glowell calibration standards ...
... FLIM system combines the space and time dimensions ... of the optical microscope to open new horizons ... light source for excitation, the decay of a ... of the decay measured. Subtle changes in ...
Biology Products: